Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 6/20 | 0.69 |
| ▸ | BRAF | P15056 | 6/20 | 0.62 |
| ▸ | BTK | Q06187 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.54 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.54 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491995 | 0.87 | CSF1R (0.84) | CSF1RBRAFBTKLCK | |
| SCHEMBL14304889 | 0.85 | TSHR (0.53) | CSF1RBRAFMEN1TSHRKMT2A | |
| SCHEMBL2494865 | 0.84 | CSF1R (0.65) | CSF1RBRAFBTKMEN1TSHR | |
| SCHEMBL1276893 | 0.82 | CSF1R (1.00) | CSF1RBRAFBTKMEN1TSHR | |
| SCHEMBL5433361 | 0.80 | TSHR (0.62) | CSF1RBRAFBTKMEN1TSHR | |
| SCHEMBL5433359 | 0.80 | TSHR (0.62) | CSF1RBRAFBTKMEN1TSHR | |
| SCHEMBL2496610 | 0.80 | BTK (0.86) | CSF1RBRAFBTKKITLCK | |
| SCHEMBL2496630 | 0.80 | SRC (0.56) | CSF1RBTKKITLCKEPHX2 | |
| SCHEMBL2495666 | 0.79 | SRC (0.62) | CSF1RBTKKITLCKRXFP1 | |
| SCHEMBL2494867 | 0.79 | CSF1R (0.70) | CSF1RBRAFBTKMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008008234-A1 | 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | CSF1R 575/4885BRAF 73/4885BTK 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.